Navigation Links
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
Date:12/7/2011

WEDNESDAY, Dec. 7 (HealthDay News) -- In November, the U.S. Food and Drug Administration revoked its approval of the drug Avastin for the treatment of breast cancer. But, a new study suggests that the drug can boost the survival of women with a specific type of aggressive breast tumor when used in conjunction with two other medications.

Avastin (bevacizumab) had been approved in the United States in 2008 as a treatment for metastatic breast cancer -- cancer that has spread to other parts of the body. It was used with chemotherapy to treat a type of breast tumor called HER2-negative.

Even though the FDA withdrew that approval, Avastin is still approved to treat some other types of cancers. Doctors may legally prescribe the drug to treat breast cancer, although insurers may refuse to cover it.

According to the FDA, the benefits of Avastin use for breast cancer do not justify the risks, which may include severe high blood pressure, bleeding, and heart attack or heart failure.

The new study was funded by Genentech, which makes Avastin, and led by Dr. Luca Gianni, director of medical oncology at the San Raffaele Cancer Center in Milan, Italy. They examined the use of the drug as a treatment for HER2-positive breast cancer that had recurred locally in the body or spread to other parts of the body. HER2-positive breast cancers are typically less sensitive to standard hormonal treatments and are often more aggressive than other types.

A total of 216 patients received Avastin with a chemotherapy treatment of trastuzumab (Herceptin) and docetaxel, while 208 received the chemotherapy alone.

An investigator and an expert review committee disagreed about how much of a difference the drug made in the risk of cancer progression or death. But overall, according to investigator and independent review committee analysis, the addition of the Avastin boosted the average months of survival (without worsening
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. FDA Revokes Approval of Avastin for Breast Cancer
2. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
3. Avastin Rejection Supported by Cancer Experts
4. FDA Panel Rejects Avastin for Breast Cancer
5. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
6. NIH study finds Avastin and Lucentis are equally effective in treating AMD
7. More Evidence Cancer Drug Avastin May Cause Harm
8. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
9. FDA Advises Against Avastin as Treatment for Breast Cancer
10. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
11. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
(Date:6/19/2013)... Citi Bike has come to New York City in a ... know for sure how many patients will choose to take advantage ... option. In fact, he’s happy about anything that might help ... more convenient for them to visit his office at 133 East ... Medicine at Back and Body Medical and an experienced NYC ...
(Date:6/19/2013)... 19, 2013 According to a June 17, ... Sunburn,” it is not uncommon for a person to suffer ... A person is likely to forget to reapply sunscreen properly ... both dry and itchy. When this occurs, it is essential ... , “Most people do not realize that milk contains proteins, ...
(Date:6/19/2013)... in emergency medicine and trauma surgery have had ... the days immediately after major injuries, including burns. ... their injuries now are at greatest risk from ... known as sepsis or from inflammation-induced multiorgan ... General Hospital (MGH) investigators that measures the movement ...
(Date:6/19/2013)... 2013) In what is believed to be the ... form of hereditary dystonia a movement disorder that ... brain stimulation report good success rates and lasting benefits. ... Disorders Program at Cedars-Sinai Medical Center,s Department of Neurology, ... of Neurosurgery at Beth Israel Deaconess Medical Center in ...
(Date:6/19/2013)... 2013) The results of three important studies have ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... continuous "machine learning" using artificial neural networks (ANNs) may ... advanced brain cancers. Another study in the June ...
Breaking Medicine News(10 mins):Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Skin Care – How to treat Sunburn 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3
... Coalition for,Pulmonary Fibrosis (CPF) announced the appointment of ... has more than 25 years of experience,overseeing all ... in,leadership for non-profit foundations such as the CPF. ... including expanding CPF fundraising,capabilities and driving its overall ...
... Assume Key Management Posts as Senior Vice Presidents, ... (NYSE: AGP ) today announced the hiring ... key management positions: Linda,Whitley-Taylor has been named Executive ... AMERIGROUP as Senior Vice President, Senior,Litigation Counsel; and ...
... Robert A Weinberg is the first recipient of the science ... Georg and Eva Klein. The prize is awarded in person ... 29 January 2008. The prizewinner, who is to be a ... to Karolinska Institutet in Stockholm for two weeks to give ...
... In today,s volatile business,environment, unforeseen market shifts ... product forecasts, sales strategies and,development plans. By ... a high-functioning Competitive Intelligence group,can alert organizations ... warn,them about potential external risks., Competitive ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... side by side to equal the width of a human ... for administering medicines and other therapeutic agents to patients. But ... after they discharge their medical payloads has been a major ... months tracking the tiny tubes inside mice, have found some ...
Cached Medicine News:Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 3Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
(Date:6/19/2013)... INDIANAPOLIS , 19. Juni 2013 ... bekannt, dass mit der Entwicklung von ... bahnbrechender Schritt in der Beschichtung mit ... die Vorteile von biokompatiblem Parylene mit ... effektive Beseitigung schädlicher Mikroorganismen auf beschichteten ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: